Patents by Inventor Susan C. Low
Susan C. Low has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230023927Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: ApplicationFiled: June 2, 2022Publication date: January 26, 2023Inventors: Robert T. PETERS, Adam R. MEZO, Daniel S. RIVERA, Alan J. BITONTI, Susan C. LOW
-
Patent number: 11401322Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: GrantFiled: March 21, 2017Date of Patent: August 2, 2022Assignee: Bioverativ Therapeutics Inc.Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, Susan C. Low
-
Publication number: 20220010000Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: ApplicationFiled: September 21, 2021Publication date: January 13, 2022Inventors: Robert T. PETERS, Adam R. MEZO, Daniel S. RIVERA, Alan J. BITONTI, Susan C. LOW
-
Patent number: 11168125Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: GrantFiled: July 22, 2019Date of Patent: November 9, 2021Assignee: BIOVERATIV THERAPEUTICS INC.Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, Susan C. Low
-
Patent number: 11084866Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: GrantFiled: March 21, 2017Date of Patent: August 10, 2021Assignee: Bioverativ Therapeutics Inc.Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, Susan C. Low
-
Publication number: 20200071385Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: ApplicationFiled: July 22, 2019Publication date: March 5, 2020Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, Susan C. Low
-
Patent number: 10513551Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: GrantFiled: March 21, 2017Date of Patent: December 24, 2019Assignee: Bioverativ Therapeutics Inc.Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, Susan C. Low
-
Publication number: 20170266309Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: ApplicationFiled: March 21, 2017Publication date: September 21, 2017Applicant: Bioverativ Therapeutics Inc.Inventors: Robert T. PETERS, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, Susan C. Low
-
Publication number: 20170267744Abstract: The present invention provides methods of reducing nonprocessed Factor VIII or a chimeric polypeptide comprising Factor VIII comprising co-transfecting in a host cell a polynucleotide encoding Factor VIII with a polynucleotide encoding a protein convertase, where the endogenous processing enzymes of the host cell are insufficient to convert all of the Factor VIII to its processed isoform; expressing a proprotein convertase from a second polynucleotide in the host cell; and reducing the nonprocessed Factor VIII by processing with said proprotein convertase.Type: ApplicationFiled: February 22, 2017Publication date: September 21, 2017Inventors: Susan C. LOW, Robert T. PETERS
-
Publication number: 20170226189Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: ApplicationFiled: April 19, 2017Publication date: August 10, 2017Inventors: Robert T. PETERS, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitoni, Susan C. Low
-
Patent number: 9725496Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: GrantFiled: April 19, 2017Date of Patent: August 8, 2017Assignee: Bioverative Therapeutics Inc.Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, Susan C. Low
-
Patent number: 9636416Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: GrantFiled: October 31, 2014Date of Patent: May 2, 2017Assignee: Bioverativ Therapeutics Inc.Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitoni, Susan C. Low
-
Patent number: 9611310Abstract: The present invention provides methods of reducing nonprocessed Factor VIII or a chimeric polypeptide comprising Factor VIII comprising co-transfecting in a host cell a polynucleotide encoding Factor VIII with a polynucleotide encoding a protein convertase, where the endogenous processing enzymes of the host cell are insufficient to convert all of the Factor VIII to its processed isoform; expressing a proprotein convertase from a second polynucleotide in the host cell; and reducing the nonprocessed Factor VIII by processing with said proprotein convertase.Type: GrantFiled: July 11, 2011Date of Patent: April 4, 2017Assignee: Bioverativ Therapeutics Inc.Inventors: Susan C. Low, Robert T. Peters
-
Publication number: 20150139947Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: ApplicationFiled: October 31, 2014Publication date: May 21, 2015Applicant: BIOGEN IDEC HEMOPHILIA INC.Inventors: ROBERT T. PETERS, ADAM R. MEZO, DANIEL S. RIVERA, ALAN J. BITONI, SUSAN C. LOW
-
Patent number: 8932830Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: GrantFiled: November 2, 2012Date of Patent: January 13, 2015Assignee: Biogen Idec Hemophilia, Inc.Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, James McGivney, Susan C. Low
-
Patent number: 8900827Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: GrantFiled: November 2, 2012Date of Patent: December 2, 2014Assignee: Biogen Idec Hemophilia, Inc.Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, James McGivney, Susan C. Low
-
Publication number: 20130281671Abstract: The present invention provides methods of reducing nonprocessed Factor VIII or a chimeric polypeptide comprising Factor VIII comprising co-transfecting in a host cell a polynucleotide encoding Factor VIII with a polynucleotide encoding a protein convertase, where the endogenous processing enzymes of the host cell are insufficient to convert all of the Factor VIII to its processed isoform; expressing a proprotein convertase from a second polynucleotide in the host cell; and reducing the nonprocessed Factor VIII by processing with said proprotein convertase.Type: ApplicationFiled: July 11, 2011Publication date: October 24, 2013Applicant: Biogen Idec Hemophilia Inc.Inventors: Robert T. Peters, Susan C. Low
-
Patent number: 8329182Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: GrantFiled: November 23, 2010Date of Patent: December 11, 2012Assignee: Syntonix Pharmaceuticals, Inc.Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, Susan C. Low
-
Patent number: 8293707Abstract: The invention provides novel heterodimeric fusion proteins comprising a first polypeptide including an alpha subunit of FSH (?FSH) linked directly or indirectly to a binding partner of neonatal Fc receptor (FcRn) and a second polypeptide including a beta subunit of FSH (?FSH) linked directly or indirectly to an FcRn binding partner. In one embodiment the FcRn binding partner includes an Fc fragment of an immunoglobulin, e.g., an Fc fragment of IgG. Also provided are methods making and using the fusion proteins of the invention. The invention provides a method for increasing fertility in a subject and a method for treating a subject having a disease state responsive to treatment by FSH.Type: GrantFiled: April 21, 2009Date of Patent: October 23, 2012Assignee: Syntonix Pharmaceuticals, Inc.Inventor: Susan C. Low
-
Publication number: 20110182919Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein said protein comprises a first and a second polypeptide chain, said first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and said second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.Type: ApplicationFiled: November 23, 2010Publication date: July 28, 2011Inventors: Robert T. PETERS, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, James Stattel, Susan C. Low